The abdomen was soft, nontender, with no evidence of hepatosplenomegaly.
siderably. 5 External beam radiation therapy is associated with slightly lower complication rates but may be marginally less effective than prostatectomy in ensuring long-term disease control and survival. 6 However, few randomized clinical trials have directly compared surgery and radiation, and more frequent selection of radiation by older patients or those with comorbidities may have biased reported survival outcomes in favor of surgery. 7 Brachytherapy (radioactive seed implantation) may offer even lower morbidity rates, but its long-term effectiveness has not been fully established. Cryotherapy (freezing) and hyperthermia (heating) are, like brachytherapy, under investigation as means to ablate tumors with minimal harm to surrounding tissue but also with unknown long-term efficacy. 6 Androgen ablation (hormonal) therapy is sometimes used as a neoadjuvant to shrink larger tumors in an attempt to make them more amenable to surgery or radiation. 8 More commonly, it is employed either as an adjuvant treatment (in patients with positive regional lymph nodes) or as a palliative therapy in those with metastatic disease. 6 Orchiectomy (surgical removal of the testicles), while an effective method of androgen ablation, has been largely supplanted by medical alternatives including diethylstilbestrol, gonadotropin releasing hormone (GnRH) analogues such as leuprolide (Lupron ® ) and goserelin (Zoladex ® ), and androgen receptor blockers including flutamide (Eulexin ® ) and bicalutamide (Casodex ® ). 6 Side effects of hormone therapy can be considerable (including hot flashes, loss of libido, loss of bone mass and muscle tone, and anemia), so its costs and benefits must be carefully weighed. Many clinicians prefer to reserve its use until disease-related symptoms have developed. Unfortunately, with the possible exception of the agent estramustine, chemotherapy appears unlikely to increase survival in prostate cancer and is used only for palliative purposes in cases of metastatic disease that have become hormone refractory. 9 Nonetheless, the combination of mitoxantrone and prednisone has been shown to reduce PSA levels and palliate pain and can benefit overall quality of life. 10 Finally, "watchful waiting" is warranted when treatment benefits are outweighed by costs, particularly in older patients in whom the potential for life extension may be minimal but quality of remaining life is paramount. Most of us are conditioned to believe that cancers must be eradicated if we are to have a chance at cure and live out our normal life span free of diseaserelated problems. In many types of cancer, this is a reasonable perspective, and eradication appears to be the only option. For many, the option of no treatment at all would be too frightening to contemplate. However, in the case of prostate cancer, many patients are older, and the tumor may be growing so slowly that it is unlikely to reach a life-threatening stage before death occurred from an unrelated cause. In other words, the idea is to die with the cancer rather than from it.
The natural history of untreated prostate cancer (watchful waiting) has been well characterized, and Gleason score (grade) may be the best single predictor of the rate of tumor progression 11 as well as overall survival time. 12 In less aggressive cancers with lower Gleason scores, the median time for the tumor to double in volume is typically 24 months or more, whereas in higher grade cancers, it is often less than 12 months. 11 For men ages 50 to 74, those with Gleason scores between 2 and 5 have a 90% or greater probability of surviving 15 years or more. Men with scores of 6 have a 70% to 80% probability, depending on age, of 15-year survival, and those with scores of 7 to 10 have a 15% to 50% probability. 12 So there seems to be a correlation in which tumors having a more aggressive histological appearance tend to progress more rapidly and become more likely to threaten host survival.
This brings us to the option of prostate cancer management through dietary modification. Interestingly, prostate cancer appears to possibly be more strongly linked to diet and nutrition than any other cancer. Furthermore, the effect of dietary factors may be related not only to the likelihood of developing prostate cancer but perhaps also to the rate at which the disease progresses. If dietary modification could slow the growth of higher-grade cancers or even those that have already spread beyond the prostate, then given the apparent association of grade, tumor doubling time, and survival, long-term survival rates for patients with more aggressive or even metastatic cancers might be increased significantly and begin to resemble the rates seen in patients with lower Gleason scores. Much research remains to be conducted on this option, but at least in theory dietary modification offers the tantalizing prospect of slowing or halting tumor progression and extending the option of watchful waiting to a larger number of patients. In addition, this approach may convey health benefits beyond the prostate including weight loss, reduction of risk for cardiovascular disease and diabetes (and perhaps other cancers), and enhanced quality of life.
In a pilot study we conducted at the University of Massachusetts School of Medicine of prostate cancer patients with rising PSA after prostatectomy, PSA doubling time (a surrogate marker of tumor doubling time in the postprostatectomy setting) was observed to increase from 6.5 to 17.7 months over the course of a 4-month dietary intervention. The intervention used a plant-based diet, modeled on the macrobiotic diet, emphasizing whole grains, fresh vegetables, legumes, and fruit. It also included stress-reduction training and group support to reinforce and add to the diet. Rates of PSA increase declined in 8 of 10 subjects, and 3 subjects had reductions in absolute PSA levels. Because the study was conducted using a population of patients whose prostate glands had already been removed, benign enlargement of the prostate and prostatitis were eliminated as possible confounders. Interestingly, all 10 subjects lost weight during the intervention, with a mean reduction of 14 pounds (7.0% of body weight), a healthy weight loss of about a pound per week. This occurred in the context of many other reported health benefits including reduction in blood pressure, serum cholesterol, and medications for diabetes; increased exercise tolerance; and overall improvement in quality of life. 13 However, it must be noted this was only one study, and a very small, nonrandomized one at that. While we are now starting a much larger randomized clinical trial of this intervention at the University of California, San Diego, School of Medicine, results are still a few years away. What is the current state of the science underlying the relationship of diet and lifestyle factors with prostate cancer?
Nutrition, Lifestyle Factors, and Prostate Cancer

International Variation in Prostate Cancer Rates
Dramatic international variations in age-adjusted incidence and mortality rates provide clues to the etiology of prostate cancer. Qidong County in China, for example, has an incidence rate of only 0.5 per 100,000 men, whereas the rate in the United States is 102.1 per 100,000. 14, 15 Among African American males, the rate is 40% higher than for the United States as a whole, accounting for the highest prostate cancer incidence of any group in the world. 2 Probably only a relatively small fraction of these differences may be accounted for by the much higher level of PSA screening and detection in the United States compared with China. Japanese men, like Chinese, also have much lower incidence and mortality rates than Americans do. Yet the large difference in rates between the United States and Japan has been observed for decades, long before the advent of PSA testing.
These disparities in incidence rates may also be explained by genetic factors associated with racial differences between Asians and Caucasians. There is growing evidence that susceptibility to prostate cancer may be familial or may be related to polymorphisms of metabolic genes, particularly those relating to the synthesis, catabolism, or response to androgens. 16 However, upon migration to the United States, prostate cancer rates in Japanese men increase 4-to 9-fold within the first generation and approximate US rates by the second generation. [17] [18] [19] While this does not rule out the possibility that genetic factors may be part of the causal chain in some cases of prostate cancer, it does suggest that environmental or lifestyle exposures, rather than genetic factors, account for most of the risk. 20 
Lifestyle Factors and Prostate Cancer
Japan is a densely populated, heavily industrialized country whose population, perhaps even more than that of the United States, is exposed regularly to many potential carcinogens. This suggests that air or water pollution, per se, is not the critical factor in explaining the much higher prostate cancer incidence in the United States. A number of studies, including both epidemiologic and laboratory investigations, have therefore focused on lifestyle factors (smoking, physical activity, sexual history, occupation, psychological stress, and diet) and patterns in search of the explanation for the differences in prostate cancer incidence rates.
With the exception of diet, most lifestyle factors have been inconsistent or equivocal in their relationship with prostate cancer incidence. While cigarette smoking has been clearly related to a number of cancers, a review of 75 epidemiologic studies (representing a mix of prospective cohort, case-control, and nested case-control studies) of smoking and prostate cancer incidence found no association in all but 3 of the studies. 21 Similarly, in a review of 23 studies investigating a link between physical activity and prostate cancer incidence, no consistent finding of an inverse association was reported. 22 However, because physical activity is difficult to measure precisely, some of these studies may have suffered from misclassification of exercise, obscuring a protective effect. In addition, while these studies controlled for age, the most well-established risk factor for prostate cancer, there may still have been confounding by other uncontrolled third variables (eg, dietary factors). 22 Cultural or societal differences in sexual practices could help explain cross-national variability in prostate cancer incidence rates, and it has been argued that such differences could point to a sexually transmitted infectious etiology. 23 In fact, sexual history has been linked, albeit weakly and in only a subset of men, to risk of prostate cancer. Several case-control studies have associated a history of a sexually transmitted disease with risk of prostate cancer. 24, 25 However, studies employing serum tests for sexually transmitted diseases have reported inconsistent findings. 26, 27 A few studies have found that men who have had vasectomies are at slightly increased risk (relative risks of 1.5-2.0) of prostate cancer, although an equal number have found no association. 28 Occupation has also been examined as a possible source of risk for prostate cancer. With the exception of farmers, no clear association with risk has been detected. Farmers have been found to have a slightly increased risk (relative risk of 1.1). 29 However, this finding in farmers may have more to do with other lifestyle attributes of farmers than with farming-related occupational exposures per se.
Finally, psychological factors and stress have not been linked to prostate cancer specifically, although they have been associated with chronic prostatitis, interstitial cystitis, and other urological conditions. 30 Certainly, it is plausible that stress could predispose men to prostate cancer. Stress has been shown to depress the activity of natural killer cells and cytotoxic T lymphocytes as well as the levels of cytokines such as interferon and various interleukins. Therefore, it may impair innate anticancer immunity. Conversely, stress management training has also been shown to modulate neuroendocrine and neuroimmune pathways 31, 32 and to have salutary effects on chronic prostatitis. 33 Unlike other possible lifestyle-related risk factors, stress is difficult to quantify and measure.
Finally, it should be noted that while stress may not be linked to prostate cancer risk, there can be no doubt that patients undergo a great deal of stress as a result of this condition. Patients often face an agonizing decision regarding which form of treatment to select. After treatment has been rendered, all patients live with the specter of potential relapse and many suffer from anxiety and depression; physical symptoms including urinary incontinence, erectile dysfunction, loss of muscle mass, osteoporosis, breast tenderness and enlargement, and hot flashes; and problems with career, finances, sexuality, marital relationships, independence, and self-care.
Diet and Prostate Cancer Incidence
Meat, dairy foods, and fat. Ecological, epidemiologic, and laboratory studies suggest that diet may constitute one of the most important environmental factors affecting the development and progression of prostate cancer. Early ecological studies most strongly associated prostate cancer incidence with international variation in intake of fat, meat, and dairy foods. More precise analytic epidemiologic studies have called the relationship of prostate cancer with fat intake into question but have largely supported an association of increased risk with consumption of meat and dairy foods.
As reviewed by Kolonel, 34 16 of 22 studies (14 case control and 8 cohort) found a positive association of meat intake with prostate cancer risk, with 15 showing odds ratios or relative risks of 1.3 or more. Nine of 16 case-control studies found positive associations between total fat intake and odds of prostate cancer. However, among the 5 of these studies that adjusted total fat for energy, the relationship with prostate cancer persisted in only 2. 34 Similarly, in a review by Chan and Giovannucci, 35 12 of 23 studies (14 case control and 9 cohort) found positive associations of dairy foods with prostate cancer risk. In the Health Professionals Follow-up Study, men whose calcium intakes (from dairy foods and supplements) were greater than 2000 mg/day, compared with those with intakes less than 500 mg/day, had a relative risk of 4.6 for metastatic and fatal prostate cancer. 36 This suggests that some constituent or property of meat and dairy foods other than total fat is critical. One possibility is that energy rather than fat (the most energy-dense macronutrient) is the critical factor. It has been long recognized that ad libitum energy feeding stimulates prostate tumorigenesis in rodents, whereas energy restriction inhibits growth. 37 Because animal food consumption is often associated with both greater fat and energy intake, most epidemiological studies of fat and prostate cancer that have been energy adjusted have not shown an association. 35 Intakes of meat and dairy foods, because of their associations with total energy intake, may also be directly associated with body weight. 38 Obesity is associated with lower serum levels of sex-hormone-binding globulin 39 and therefore could lead to higher circulating levels of unbound testosterone, a putative prostate tumor promoter. Obesity is also linked to insulin resistance and increased levels of insulin-like growth factor (IGF). IGF stimulates the growth of both normal and prostate cancer cells in the prostate gland. 40 Another means for explaining the association of meat and dairy foods, but not total fat intake, with prostate cancer incidence is that some types of fat, but not others, may stimulate prostate carcinogenesis, a possible explanation that may be obscured by simple examination of total fat. For example, arachidonic acid, synthesized endogenously from omega-6 fatty acids and also found preformed (in cell membranes) in foods of animal origin, has been shown to stimulate the growth of both LNCaP (hormone-sensitive) and PC3 (hormone-insensitive) cell lines. 41 In fact, arachidonic acid is as effective as testosterone in stimulating growth of hormone-sensitive LNCaP cells. 41 Furthermore, arachidonic acid serves as a substrate for production of a number of eicosanoids, particularly the 5lipoxygenase product 5-hydroxyeicosatetraenoic acid (5-HETE) that has also been shown to be a potent stimulant of human prostate cancer cell growth. 42 Conversely, while arachidonic acid sharply increases production of 5-HETE, inhibition of 5-lipoxygenase blocks 5-HETE and induces massive apoptosis in both LNCaP and PC3 cell lines. 43 Plant foods and carotenoids. Another possibility is that diets high in meat and dairy foods may be relatively lower in plant foods and their potentially anticarcinogenic phytonutrients. A number of plant foods, including whole cereal grains, vegetables, legumes, and fruits, have been examined in cohort and case-control studies with respect to their potential for protecting against prostate carcinogenesis. As summarized in a recent review, 8 of 16 studies (13 case control and 3 cohort) reported inverse associations of specific or total vegetable intake with prostate cancer risk, whereas 8 reported no association. None reported increased risk. The strongest protective effects were seen for legumes, pulses and nuts, carrots, leafy greens, cruciferous vegetables (cabbage family), and tomatoes. 44 Cruciferous vegetables have been found in 2 population-based studies to be associated with a reduction in prostate cancer incidence. 45, 46 Indole-3carbinol, derived from diets rich in cruciferous vegetables, inhibits the growth of PC-3 human prostate cancer cells by inducing G1 cell cycle arrest leading to apoptosis and regulates the expression of apoptosisrelated genes. 47 In addition, cruciferous vegetables are rich sources of the isothiocyanate sulforaphane. Sulforaphane has been shown to up-regulate phase II enzymes in a variety of human prostate cancer cell lines, an induction that appears to be mediated by increased transcription of the NQ0-1 gene. 46 Closely related to vegetable and fruit intake is a class of micronutrients, carotenoids, which could affect prostate cancer risk. Carotenoids promote differentiation of epithelial tissues, perhaps in part through the provitamin A properties of certain members of this class (such as β-carotene). Carotenoids may also exert anticancer effects independently of provitamin A effects through antioxidant protection against free radical damage to DNA, carotenoidregulated production of gap junction proteins, or other mechanisms. 48 While earlier epidemiologic studies of carotenoids and prostate cancer risk were ambiguous, 49 more recent studies have suggested a possible protective role for specific, though not total, carotenoids. 44 Much interest has focused on lycopene as a result of in vitro studies, suggesting an inhibitory effect on prostate cancer. 50 However, epidemiologic support for a protective effect has been mixed, with only 1 of 8 cohort and case-control studies, but 2 of 3 plasma studies, showing inverse associations. 44 Vitamin E and selenium. Other micronutrients that have been extensively explored in relation to prostate cancer risk include vitamin E and selenium. While most epidemiological studies of vitamin E intake have been inconsistent, vitamin E supplementation was associated with a 40% reduction in prostate cancer incidence and mortality in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Trial, 51 as a secondary finding in this study. Vitamin E supplementation has also been consistently associated, in secondary analyses of data from clinical trials, with decreased risks of advanced and fatal prostate cancers but, intriguingly, only among smokers. [52] [53] [54] Interest in selenium results from several lines of research. Ecologic studies have shown lower cancer mortality rates in areas with higher soil or plant selenium or higher per capita intake. 55 In cell culture, selenium inhibits growth and induces apoptosis in prostate cancer cells. 56, 57 Most, but not all, epidemiological studies have also correlated high plasma and high toenail selenium levels with lower prostate cancer incidence and mortality. 55 On the basis of these lines of evidence, selenium appears to be a promising agent for chemoprevention of prostate cancer. Two studies of selenium on markers of progression are now under way. A third, and by far the largest intervention, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) will enroll 32,000 men over 12 years. 58 Soy and green tea. Studies of the antiprostate cancer potential of a number of other specific foods and phytonutrients have also been conducted. Among these, a great deal of interest has focused on the potential beneficial effects of soy foods and soy isolates. In part, this is because soy foods are widely consumed in Asian countries with lower prostate cancer incidence. Furthermore, soy isoflavones have shown a remarkable array of anticancer properties in laboratory studies including inhibition of DNA gyrase, estrogen receptor binding, angiogenesis inhibition, and induction of apoptosis. 59 In animal models, administration of genistein modestly inhibited human prostate cell xenografts 60 and reduced prostate cancer yield. 61 However, other aspects of Asian diets that could themselves account for the lower risk confound ecological studies. Furthermore, epidemiological studies have been equivocal with weak beneficial effects observed in a few studies. 59 A final dietary constituent for which much interest has emerged is green tea. Green tea is widely consumed in Asian countries with lower prostate cancer risks. Green tea has been shown to induce apoptosis, inhibit a wide variety of tumors (lung, skin, esophagus, stomach, liver, duodenum, small intestine, and pancreas) in animal models, 62, 63 and contain catechins that, in rats, inhibit 5-alpha-reductase. 64 Therefore, its use as a chemopreventive agent for prostate cancer in humans is under active consideration. There have been only a few epidemiological studies of green tea, and these have been equivocal, with some showing a mild reduction in prostate cancer risk (relative risks or odds ratios of 0.6-0.9) and others no effect. 63 
Diet and Prostate Tumor Progression and Metastasis
Preliminary evidence suggests that dietary factors may influence not only prostate cancer incidence but also its progression, potential for metastasis, and perhaps even long-term survival after treatment. Several dietary factors have been associated with risk of advanced, metastatic, or fatal prostate cancer. Consumption of both red meat and dairy products have been associated with increased risk of metastatic prostate cancer. 65 Vitamin E supplementation, as noted above, is associated with decreased risks of advanced and fatal prostate cancers among smokers 52, 53, 66 and may delay tumor progression. 67 These observations suggest that dietary factors continue to exert their effects long after disease inception. They also raise the intriguing question of whether modifying these factors, after the disease has been detected, could alter its subsequent course. Substantive dietary changes, marked by adoption of plantbased macrobiotic diets, have been associated with prolonged survival and instances of remission of bone metastases in men with advanced disease in uncontrolled studies and anecdotal data. 68 More recently, serum from subjects upon completion of a low-fat, high-fiber diet and exercise intervention was found to inhibit the growth of LNCaP, but not PC-3, human prostate cancer cells. Interestingly, the intervention also resulted in a reduction in subjects' serum levels of free testosterone, suggesting that the inhibitory effect of diet and exercise on prostate cell growth may have been hormonally mediated. 69 This is consistent with earlier reports that suggested that low-fat, high-fiber diets might modulate circulating androgen levels. 70, 71 Finally, as noted earlier, in prostate cancer patients with rising PSA after prostatectomy, PSA doubling time (a surrogate marker of tumor doubling time) was observed to increase from 6.5 to 17.7 months over the course of a 4-month plant-based diet and stressmanagement intervention. 13 
Summary of Findings Regarding Diet, Lifestyle, and Prostate Cancer
While not fully conclusive, dietary relationships with prostate cancer appear to be strong in several areas. First, the ecological data show extremely strong international differences in prostate cancer incidence and mortality. Migrant studies support the concept that these differences are due more to environmental factors, possibly dietary, than to genetic variation. Epidemiologic and laboratory studies further support the concept that disparities in rates owe to dietary, rather than to other environmental or lifestyle, differences and begin to describe higher and lower risk dietary patterns.
A high level of consumption of foods of animal origin, particularly meat and dairy, is fairly consistently associated with higher prostate cancer risk. Plant foods, especially carotenoid-rich Brassica family vegetables (broccoli, kale, mustard greens, etc), are associated with lower risk. Other dietary constituents including soy, green tea, selenium, and vitamin E may also be protective. Certain dietary approaches, such as vegetarianism or macrobiotics, integrate these factors into a coherent, balanced pattern based on whole grains, vegetables, legumes, and fruit. These approaches appear, on the basis of preliminary data, to possibly retard prostate tumor progression in humans and, in several medically documented case histories, to be associated with spontaneous remissions of metastatic disease.
Specific Recommendations
Given this patient's age of 67 and Gleason score of 6, he has about a 75% probability of surviving another 15 years with only watchful waiting. Given that his life expectancy, as a 67-year-old man, is also about 15 years, there is a relatively low, but not negligible, probability that he may encounter problems or die prematurely from the cancer. On the other hand, there is a relatively low, but also not negligible, probability that he may experience complications such as urinary incontinence or erectile dysfunction should he elect to be treated. What is he to do?
Ultimately, this is a question that only the patient can answer. I believe that the best one can do with a patient like this, where the research evidence does not strongly support one approach or another, is to present him with the most honest and accurate information about the potential risks and benefits of his different treatment options and to assist him in weighing his personal priorities. For example, does he value a higher chance of long-term survival or a lower risk of complications? Does he prefer strong certainty of a moderately good outcome or only fair certainty of a potentially better outcome? Hopefully, with this sort of guidance, the patient will arrive at the decision he can best live with. He currently seems to be leaning toward brachytherapy after completing neoadjuvant hormone therapy and, assuming he has been well informed about his options, this would appear to be a very reasonable choice.
Given what we already know about the role of diet in prostate cancer, dietary and supportive lifestyle changes would probably represent a reasonable treatment strategy for this patient either alone or as an adjunct to other treatment. If he goes ahead with brachytherapy (a modality with an uncertain longterm track record), dietary modification may help to increase his odds and ensure that his prostate cancer does not recur after treatment or, in the event that micrometastases are already present, that the disease does not progress to the point that it ever becomes life threatening.
Paradoxically, what we already know about the patient's nutritional status and excessive body weight give reason for optimism about the dietary approach. With a weight of 190 lbs. and height of 5′6″, he has a body mass index of more than 30, a level considered obese by most experts. Obesity may increase circulating testosterone levels as well as the conversion of testosterone via the enzyme 5-alpha reductase to the more strongly prostate tumor-promoting moiety dihydrotestosterone. He also consumes a standard American dietary pattern, itself associated in a variety of ways with heightened prostate cancer risk. Therefore, there is likely to be enormous potential for improvement.
An appropriate diet and lifestyle regimen for the patient would consist of the following: such as aduki, lentils, and chickpeas, or soy foods such as tempeh and tofu); 3. fruit (approximately 1 cup/day of cooked or raw seasonal fresh or dried fruits such as apples, pears, berries, and melons); 4. other foods for regular use such as seeds (sunflower, sesame, and pumpkin), nuts (walnuts and almonds), miso soup (using unpasteurized brown rice or barley miso), sea vegetables, fish (optional), whole meal bread, and naturally prepared pickles and condiments; 5. beverages including green, twig (kukicha), and various other herbal teas (chamomile, mint, red clover, saw palmetto) and diluted fruit juice (apple, pear, berry), vegetable juice (carrot, parsley, tomato), grain coffee (Cafix), and spring water;
6. supplements including 1 tblsp/day of cold-pressed, refrigerated omega-3 oil (such as flax), daily antioxidant with mixed carotenoids (including lutein and lycopene), vitamin E, selenium, and zinc; 7. daily exercise of 20 to 40 min/day of walking, swimming, tennis, t'ai chi, yoga, or other gentle cardiovascular, weight bearing, and flexibility exercises (caution with biking because of pressure on the prostate); 8. daily practice (10-15 min/day) of meditation or prayer; 9. acupuncture, massage, and Chinese herbs to support diet and lifestyle change and, if needed, to counter side effects of conventional therapies; and 10. seeking out social and emotional support from and provide support to others.
However, dietary changes of this magnitude are not easy to make or maintain. The patient will require a great deal of education, structure, and physician encouragement and support. Nutritional counseling, cooking instruction, and group and spousal support will also be critical. Stress reduction training may also be helpful in assisting him to work through feelings of loss and marshall his energies toward self-healing. Yet if he is able to accomplish this, he is likely to experience secondary benefits that go far beyond his cancer. His hypertension would likely improve, weight loss would reduce stress on his knees and lessen his risk of developing further herniations, and dietary changes would likely reduce aggravation and permit healing of his peptic ulcer. In short, he may be granted a new lease on life with an enhanced quality of living. So regardless of what else he does, I would strongly encourage him to modify his diet and to adopt other healthy supportive lifestyle changes as well.
If diet and lifestyle changes are shown, in future clinical trials, to significantly improve the prognoses and outcomes of patients, then much of what we currently believe to be the case about optimal management will need to be revisited. Each of the current primary treatment strategies (surgery, radiation, hormonal therapy, watchful waiting, etc) will need to be reevaluated in combination with dietary modification. However, if this occurs, it will be a complex undertaking that will take many years. In the interim, we must use the best available data, along with good judgment and intuition, to guide patients such as the individual in this case.
